Literature DB >> 22503347

Promoter region polymorphisms in the transforming growth factor beta-1 (TGFβ1) gene and serum TGFβ1 concentration in preeclamptic and control Iranian women.

Sadegh Feizollahzadeh1, Robabeh Taheripanah, Masood Khani, Babak Farokhi, Dawar Amani.   

Abstract

Preeclampsia (PE) is a pregnancy associated disorder characterized by hypertension and proteinuria, which causes neonatal and maternal morbidity and mortality. The Th1/Th2 cytokine paradigm of the immune adaptation in pregnancy is now expanded to include Th1/Th2/Th17 and regulatory T (Treg) cells. Among cytokines, TGFβ1 has properties that justify evaluation of its role in PE etiopathology. In this investigation the polymorphisms of the TGFβ1 gene at promoter region, positions -800G→A and -509C→T, were studied in 142 PE and 140 normal pregnant female subjects using PCR-RFLP. Additionally, serum TGFβ1 was determined by ELISA. At position -800G→A genotypes and allele frequencies showed no significant differences between PE patients (GG 73.9%; GA 21.1%; AA 4.93%) and normal control (GG 70%; GA 28.6%; AA 1.4%) women. However the AA genotype at this position was more frequent in PE patients than in the control group. At -509C→T position, genotypes and allele frequencies showed no significant differences between PE patients and control individuals. The CC genotype at -509C→T position was more prevalent in PE patients than in the control group. The mean serum TGFβ1 level was significantly higher (62.14 ng/ml) in PE patients compared with pregnant and non-pregnant control groups (and 47.01 and 40.68 ng/ml, respectively). In conclusion, the promoter region polymorphisms of TGFβ1 may not be associated with PE, but serum levels of this cytokine may contribute to the etiopathology of PE.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503347     DOI: 10.1016/j.jri.2012.02.006

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  7 in total

1.  Preeclampsia-Derived Exosomes Imbalance the Activity of Th17 and Treg in PBMCs from Healthy Pregnant Women.

Authors:  Ramin Pourakbari; Forough Parhizkar; Mohammad Sadegh Soltani-Zangbar; Parisa Samadi; Majid Zamani; Leili Aghebati-Maleki; Roza Motavalli; Ata Mahmoodpoor; Farhad Jadidi-Niaragh; Bahman Yousefi; Hossein Samadi Kafil; Mohammad Hojjat-Farsangi; Shahla Danaii; Mehdi Yousefi
Journal:  Reprod Sci       Date:  2022-09-26       Impact factor: 2.924

2.  Transforming growth factor beta1 (TGFβ1) polymorphisms and breast cancer risk.

Authors:  Davar Amani; Ahad Khalilnezhad; Abbas Ghaderi; Norrio Niikawa; Ko-ichiro Yoshiura
Journal:  Tumour Biol       Date:  2014-01-15

3.  Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia.

Authors:  Luiza O Perucci; Karina B Gomes; Letícia G Freitas; Lara C Godoi; Patrícia N Alpoim; Melina B Pinheiro; Aline S Miranda; Antônio L Teixeira; Luci M Dusse; Lirlândia P Sousa
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

Review 4.  The prion protein family: a view from the placenta.

Authors:  Samira Makzhami; Bruno Passet; Sophie Halliez; Johan Castille; Katayoun Moazami-Goudarzi; Amandine Duchesne; Marthe Vilotte; Hubert Laude; Sophie Mouillet-Richard; Vincent Béringue; Daniel Vaiman; Jean-Luc Vilotte
Journal:  Front Cell Dev Biol       Date:  2014-08-08

Review 5.  Transforming growth factor β signaling in uterine development and function.

Authors:  Qinglei Li
Journal:  J Anim Sci Biotechnol       Date:  2014-11-14

Review 6.  Polymorphisms and plasma level of transforming growth factor-Beta 1 and risk for preeclampsia: a systematic review.

Authors:  Xun Li; Lin Shen; Hongzhuan Tan
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

7.  Circular RNA hsa_circ_0026552 inhibits the proliferation, migration and invasion of trophoblast cells via the miR‑331‑3p/TGF‑βR1 axis in pre‑eclampsia.

Authors:  Li Shan; Xiaofei Hou
Journal:  Mol Med Rep       Date:  2021-09-15       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.